Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

April 30, 2020

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 72 min

Earnings Call Speaker Segments

Jake Elguicze

executive
#1

Hello, everybody, and thanks for joining us on the Teleflex Inc. First Quarter 2020 Earnings Conference Call this morning. You can find the press release and the slides that go with this call on our website at www.teleflex.com. Also, just to note, this call is being made available on our website, and a replay can be accessed by calling (855) 859 to 2056, or if you're calling internationally, (404) 537 to 3406, with pass code 7545905. On the line with us today are Liam Kelly, our President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks, and after that, we'll open things up for Q&A. Before we get started, I want to remind everyone that certain matters we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides. Please be aware that these statements are, in fact, forward-looking in nature, and they carry risks and uncertainties, so actual events or results could differ materially. Among the factors that might cause actual results or events to differ materially are those referenced in the press release we issued today, along with our filings with the SEC, including our Form 10-K, which you can access on our website. With that said, I'd like to hand the call over to Liam.

Liam Kelly

executive
#2

Thanks, Jake, and good morning to all of you; I'm glad to have this chance to talk with you today. Before I walk through how we performed this quarter, I want to express my sympathy for everyone affected by the coronavirus, and also my heartfelt appreciation for all health care workers — Teleflex employees who have gone back into clinical practice included — who expose themselves to danger in the fight against COVID-19 each day. I also want to pause and acknowledge the Teleflex team members worldwide. The last few months have been anything but ordinary, and our people keep inspiring me, because they have risen to the occasion in remarkable ways so that we can get our products to the hospitals, clinicians and patients who need them most. So, a huge thank you goes out to the entire Teleflex workforce. Let me now turn to our quarter 1 results. For Teleflex, the first quarter of 2020 represented a strong beginning to the year. That's especially true given how the COVID-19 pandemic escalated across the globe. In quarter 1, our constant currency revenue growth came in at 4%. And if you look at it on a selling day neutral basis, constant currency revenue growth stood at roughly 5.5%. The performance of our Americas, EMEA and OEM segments powered quarter 1 revenue growth. Our Asia segment, however, saw a decline stemming from COVID-19. Turning to margins, adjusted gross and operating margins came in at 57.3% and 25.6%, respectively; on a year-over-year basis, that works out to an increase of 60 basis points for gross margin and 190 basis points for operating margin. And looking at adjusted earnings per share, we posted a strong year-over-year gain of 21.4%, with earnings per share reaching $2.72 for the quarter. I'm very happy with how well we drove significant leverage down the income statement while steering through an extremely challenging operating environment. It speaks to the strength of the diversified global portfolio that we have assembled over the past few years. Now, I think it would be useful to give some context on how COVID-19 affected our first quarter results, in our view. As a reminder, the full year 2020 financial guidance we gave earlier assumed a negative COVID-19 impact of between $5 million and $10 million on revenue and between $0.05 and $0.10 on adjusted earnings per share. All of that was assumed to relate to our business in China. And it was expected to be only a quarter 1 event. Keep in mind that at the time we provided our guidance on February 20, COVID-19 was largely only affecting China. When we moved through Q1 — January, February, and the opening 2 weeks of March — results came in mostly as we had anticipated at the start, and apart from China we didn't observe much of a negative effect. But once the virus started spreading more widely around the globe, and with the American College of Surgeons and the surgeon general putting out guidance that hospitals must delay any procedures deemed nonemergent or elective, a sharper negative impact emerged over the quarter's final few weeks. Though we figure just 1/3 of our product portfolio ties to nonemergent or elective procedures, our business still absorbed a hit. Through those closing weeks of March, this added headwind showed up mostly in the Americas, and chiefly in our Interventional Urology, Interventional Access and Surgical product lines. We did pick up some offsets in the Americas from higher sales of particular respiratory products. Even so, that couldn't make up for revenue and margins lost to canceled procedures. Moving to EMEA; demand rose considerably for certain Vascular Access, respiratory and Anesthesia products, and we believe our results in that region gained from stronger demand for products we sell to treat patients with COVID-19. In Asia, meanwhile, the COVID-19 impact matched what we had previously assumed. All told, for the quarter we faced a revenue headwind somewhat worse than what our initial guidance contemplated, while at the adjusted earnings line the headwind landed in line with the high end of our original estimates; this happened even though our guidance had assumed an impact in China only, since the virus has moved past China to the rest of the world. Now I'd like to give you our thinking as we look toward the rest of the year. Above all, I want to share the guiding principles we set up as a framework for making decisions throughout the crisis: employee and customer safety first, communicate with transparency, and manage the business to accelerate through the recovery. On safety first, let me simply state that our workers' health and safety comes before everything. So we've put in place best practices for health and safety guidelines consistent with the World Health Organization, the CDC and local health authorities. On communicating with transparency, we've set up a global crisis management team to coordinate our actions and keep employees engaged with regular updates. And on managing the business to accelerate through the recovery, we stay committed to investing whatever resources are needed to support increased demand due to COVID-19 for certain product lines while keeping adequate inventory on hand to benefit from a phased recovery. Second. Up to now, we've seen minimal disruptions in our global supply chain. That said, this situation is very fluid and things can shift fast. To give you one illustration, owing to specific limitations imposed by authorities in India as well as Malaysia, at particular sites in those nations we aren't right now running at full capacity. Yet no essential respiratory, airway or vascular items needed for combating COVID-19 have been affected by this limitation. In fact, when it comes to key respiratory product families, across the last 4 to 6 weeks we've managed to secure substantial production gains. Actually, just a handful of days before this earnings call, we found out that the Malaysian government was lifting particular curbs it had earlier put in place, which we anticipate will let us get into a position to bring our production capacity within our Malaysian facility back up to 100% during the coming week; and although we can keep doing our utmost to satisfy customer demand for the majority of our products, we are compelled to put particular respiratory, Vascular and Anesthesia products on allocation because of heightened order rates and longer delivery times tied to those products. Third, following trends that started in the second half of March, we anticipate that postponement of certain nonemergent and elective procedures will keep hurting our Interventional Urology business along with certain portions of our Surgical and Interventional Access product lines. As I said before, we estimate that just about 1/3 of our product portfolio gets used within procedures that can be deferred. That doesn't mean all of these procedures are being deferred, given the criticality of some patients.

Liam Kelly

executive
#3

We also think that postponement can't go on forever, since patients' underlying conditions won't get better just because they're waiting for a procedure to be done. On the flip side, when the United States starts reopening, we think parts of our portfolio could gain from a rebound in outpatient and day case elective procedures as states hit the White House Phase One status; yet the rest of our portfolio hit by COVID would bounce back in Phase Two. Also, I want to let the investment community know that capital equipment exposure across our portfolio is quite limited. Our view is that UroLift procedures would be the earliest to return in Phase One. Roughly 60% of those procedures take place in an office or ASC setting. From conversations we've had with a number of high-volume UroLift users, they believe they should be able to handle a substantial share of the procedures they'd had to put off. The other 40%, done in the hospital, need no overnight stay and are likewise classified as Phase One. We believe that when consumer confidence is restored, a recovery will start to show up here as well. After UroLift procedures resume, we'd expect our Interventional Access and Surgical business to be the next to recover. So we've set up our business to capitalize on that higher demand when it arrives; that involves building some safety stock and ensuring we hold the right amount of inventory. On top of that, we haven't furloughed or laid off any employees. Instead, we wanted to ensure we keep our key sales and clinical personnel and keep them motivated as we look ahead to procedures coming back. That said, to partially offset the negative financial hit from the drop in certain procedures, we've acted to reduce operating expenses. This covers adjusting certain executive and management compensation plus cutting any discretionary spending that wasn't essential to the organization. We've also decided to push back our national direct-to-consumer UroLift campaign. That being said, since we can't precisely forecast the extent or timing of the recovery, we're withdrawing the 2020 financial guidance we previously gave. Even though we have to pull our 2020 guidance, I'm still confident that our long-term global opportunity stays substantial, and our business is well placed to ride out the COVID storm and speed up down the road. That said, let's shift our focus to first quarter financial results. I'll start with a review of our reportable segment revenues; and unless I say otherwise, the growth rates I mention are on a constant currency basis. The Americas posted revenues of $358 million in the first quarter, an increase of 4.3%. Meanwhile, on a selling day neutral basis, the Americas grew approximately 6%. In this region, the expansion came from our Interventional Urology, Vascular Access, and respiratory product lines, and it would have been much stronger if COVID-19 hadn't weighed on it. First-quarter revenues for EMEA came in at $156.1 million, which is 3.8% growth. On a selling day neutral basis, EMEA also posted roughly 6% growth. Broad strength across our Vascular Access and respiratory portfolios largely fueled the growth here. And as I mentioned before, we believe EMEA gained from increased ordering tied to COVID-19. Now on to Asia. First-quarter revenues reached $53.1 million, a decline of 9.2%. Selling day differences didn't affect this region's growth rate, but we estimate that without the impact of COVID-19, we would have seen positive constant currency revenue growth. And finally, our OEM business posted first-quarter revenues of $63.4 million, an increase of 17.5%. As with Asia, selling day differences had minimal effect on our OEM business. A combination of extra revenue from the HPC acquisition plus higher sales volumes of existing products drove the growth. We don't think COVID-19 materially affected our OEM business in the first quarter. That said, this could shift as we progress through the year. Regarding the HPC acquisition, integration work is progressing well, and I'm quite pleased with how the business is performing under our leadership. Let's turn now to discussing our revenues by global product category. In line with my earlier comments about our reportable segments, commentary on global product category growth will likewise be on a constant currency basis. Beginning with Vascular Access. Thanks to growth in both our PICC and EZ-IO products, quarter 1 revenues rose 5.6% to $150.3 million; we estimate that COVID-19 boosted the growth rates of our vascular products in the first quarter, while one less selling day dragged growth down. Moving to Interventional Access. First quarter revenue was $99.9 million, a decline of 2.3%. During the quarter, growth in MANTA, OnControl, and intra-aortic balloons was more than offset by declines in complex and drainage catheters along with one less selling day. Our Interventional business also had a tough comparison in Q1 since revenue tied to our divested catheter reprocessing products was still present in quarter 1, '19. In addition, we estimate that COVID-19 hurt the growth rates of our Interventional Access products in the first quarter, as some nonemergent procedures were canceled. Now to Anesthesia. Quarter 1 revenue was $75.7 million, a decline of 3.9%. Lower sales of laryngeal masks and certain regional Anesthesia products, plus the effect of one less selling day, caused the revenue decline. As for COVID-19, we estimate its impact in the first quarter was negligible. Shifting to our Surgical business. Sales came in at $75.4 million, down 11.5%, with the bulk of that pressure tied to COVID-19, the Sterigenics Atlanta facility closure, and one fewer selling day. Now on to Interventional Urology. Q1 revenue rose 24.3%, reaching $74.2 million. During January and February, plus the opening couple of weeks of March, growth rates stood well above the quarterly figure we posted, since UroLift had gotten off to a tremendous start to the year. Sadly, elective procedure cancellations stemming from COVID-19 hit this line harder than anything else in our portfolio. As mentioned before, given that UroLift procedures take place in a lower-acuity outpatient environment, we expect UroLift to rank among the earliest procedure types to resume once the United States reopens; and lastly, our other category, made up of respiratory and urology care products, posted 9.2% growth, reaching $91.7 million. We believe that growth over the quarter was mostly attributable to rising demand for respiratory items like filters and humidification stemming from COVID-19. That wraps up my remarks on Q1 revenue performance. I'd like to hand the call to Tom now for a closer look at our first quarter financial results. Tom?

Tom Powell

executive
#4

Appreciate that, Liam, and good morning to all of you. Since we already went through how the company's revenue performed, I'll pick things up at the gross profit line. Adjusted gross profit for the quarter came to $361.1 million, compared with $347.8 million in the same quarter last year, which works out to roughly a 4% gain. Adjusted gross margin for the quarter was 57.3%, up 60 basis points from the year-ago period. That gross margin improvement came mainly from a favorable product mix, gains tied to cost improvement initiatives, and the effect of favorable swings in foreign currency exchange rates. The mix benefit we saw during the quarter was held back by COVID-19, since the negative revenue impact tended to fall disproportionately on products carrying higher gross margins, among them UroLift, Surgical and Interventional Access. Because of the lower revenue outlook brought about by COVID-19, we have taken a proactive look at expenses to find sensible ways to offset the earnings hit related to COVID-19, while simultaneously protecting Teleflex's capacity to bounce back quickly once elective procedures return. Gross margin expansion together with the OpEx measures produced a 190 basis point lift to adjusted operating margin, which reached 25.6% for the first quarter. Within the first quarter operating margin results was a foreign exchange headwind of roughly 50 basis points. Adjusted operating profit was $161.6 million, versus $145.6 million a year earlier, or a rise of approximately 11%. Continuing further down the income statement: net interest expense for the quarter came to $14.9 million, a decline of approximately 34% from the prior year quarter. That drop in interest expense mainly reflects lower interest rates tied to our variable interest rate debt instruments, along with a cross-currency swap agreement we entered into during the first quarter of 2019. Now on to taxes: for the first quarter of 2020, our adjusted tax rate was 12.5%, compared with 14.8% in the prior year period. The year-over-year reduction in our adjusted tax rate stems primarily from a more favorable mix of taxable income in the first quarter of 2020 relative to the prior year period, partly offset by a smaller benefit from stock-based compensation. At the bottom line, first quarter adjusted earnings per share rose 21.4% to $2.72. An adverse foreign exchange impact of $0.10 is included in that result. All in all, we are quite pleased with the strong bottom line growth despite the headwinds from COVID and FX. Shifting now to a few balance sheet and cash flow highlights: for the first quarter of 2020, cash used from operations was $11.5 million, compared with an inflow of $60.2 million in the prior year period. That decrease is explained by a $53.9 million increase in contingent consideration payments, largely tied to milestone payments arising from the acquisition of NeoTract. In addition, a $10 million pension contribution was made in the first quarter of 2020. On the whole, the balance sheet remains in good shape. When we closed out the first quarter, we held $406 million in cash, with $182 million of that sitting in the U.S. At the close of the quarter, net leverage stood at roughly 2.6x, which leaves us with plenty of breathing room relative to the covenant requiring us to remain under 4.5x. And finally, we don't face any material debt maturities in the near term. After that, to stress-test how our liquidity looks given COVID-19, we ran a number of recovery scenarios with differing recovery time lines. In every one of those scenarios, Teleflex keeps enough liquidity to carry out our plans and preserve comfortable covenant headroom, with additional borrowing capacity still available to us through our existing credit facility. That wraps up my prepared remarks. At this point I'd like to hand the call back to Liam for his closing commentary. Liam?

Liam Kelly

executive
#5

Thanks, Tom. To wrap up, our first quarter performance came in strong, which demonstrates how much we gain from having a diversified footprint worldwide. It's tough to say whether the road back will look like a V, a U, or perhaps even a W, but as a company, we'll keep watching the reopening plans closely, state by state and nation by nation, so that we can seize the fullest opportunity as those states and nations reopen. We've brought digital tools into our business units, since we believe that can work well for training clinicians on how to use our products safely and effectively. We'll run the business carefully while remaining committed to capturing the long-term promise of our worldwide product portfolio. To end, I want to thank our employees once more, who keep making, shipping, and supporting the products that get purchased in the battle against COVID-19. And the way Teleflex employees have responded has left me humbled, as we keep fulfilling what we owe our customers, their patients, and our investors. That's all for my prepared comments. At this point, I'll hand the call back to the operator so we can begin Q&A.

David Lewis

analyst
#6

Nice work on a quarter that held up well. Two things from me. First I'll ask about UroLift, then I'll shift to a different segment. Liam, you brought up UroLift a number of times and how confident you are in a rebound. Could you walk through what's happening with the business? What was the decline at the worst point? Has there been any improvement since the April bottom? You've emphasized ASC access as a benefit, but what's your view on the typical patient being 70 years old and how referrals or patients might respond? Then I have a quick follow-up about respiratory.

Liam Kelly

executive
#7

Sure. Thank you, David. I'll cover the patterns we observed during January and February for UroLift, and then March. That should help the investment community understand what happened when procedures were canceled. Looking at January and February, UroLift was expanding at a bit more than 38%. Then in March, it fell 3.3%. During the final 2 weeks of March, versus the first 11 weeks, we saw roughly a 64% drop in the business across those last 2 weeks as cancellations occurred. Regarding the other part of what you asked — why we expect a recovery, plus access and patient age — first, the typical UroLift patient's age isn't 70. It's a little above 60. So we certainly don't have men who are 70-plus or in a higher-risk group. I believe it comes down to customer confidence and consumer confidence as people return to these centers. My confidence that UroLift will bounce back fast rests on several points. First, in my conversations with urologists, we know there's both capacity and willingness to perform UroLift procedures. We ran a survey of more than 170 urologists, and 60% of them were considering scheduling changes after COVID. Investors who know UroLift well will recall that 60% of UroLift procedures take place outside the hospital, and we think consumer confidence will come back first in the ASC and office setting. UroLift will clearly gain from states entering Phase One along with CMS, the American College of Surgeons, and other leading organizations agreeing that outpatient procedures will be the first to recover. That adds to our confidence too. The procedure takes under 1 hour in a doctor's office, an ASC, or even a hospital, and it's the only one that can help prevent sexual dysfunction. Also, a third point: there's a powerful monetary motivation for urologists, plus our sales team, to get back to full speed as fast as they can. And when you examine the sequence in which states are moving, we devoted some time to analyzing that. The 18 states and territories that are set to reopen soon, or will reopen before long, represent roughly 32%. Right behind them are 4 additional states arriving shortly, and those make up another 27%. So approximately 60% of the states, the ones where our business takes place, are going to reopen before long. And the final thing I'll mention is that in the survey we conducted, David, it showed that BPH ranks among the top 4 disease states that urologists are putting priority on as they return to work, sitting behind categories such as prostate cancer and kidney stones, which clearly are emergent and require attention — are emergent and will cause the patient to develop pain. And I think the last remark I'll offer, David, is that our DTC campaign, once we get it online, might serve as a catalyst too, to motivate men to visit these practices. Apologies for the lengthy response, but I believe there's quite a bit packed into that question.

David Lewis

analyst
#8

That's an amazing level of detail, Liam, precisely what I believe investors wanted. Let me just ask one quick thing here to finish up. Two segments that proved more resilient in Q1 were respiratory and OEM. I'm just curious how you expect those segments to perform going forward.

Liam Kelly

executive
#9

You're right regarding our respiratory business; and once more, I'll offer the same kind of commentary about respiratory that I provided on Interventional Urology. During January and February, respiratory saw a slight decrease, roughly 2.2%; and that's expected, distributors usually reduce inventory in the opening couple of months of the year; in March, our respiratory business expanded by 44%, resulting in over 13% growth for the quarter, and that's obviously due to COVID-19 having an effect, we witnessed first in EMEA rising orders for respiratory products, then soon after in our American business. And then regarding our OEM business, once again, it's a fantastic business. It grew by 17.5%. No meaningful day adjustment there, roughly half of the growth came from the acquisition and the other half approximately came from the core business. So OEM business has kept performing superbly as it has done over the past number of years. As we go forward, we'll watch the COVID impact on the OEM closely. As I mentioned in my prepared remarks, it's hard to determine that as we go forward because we manufacture products for other companies, and we don't yet know what the impact is to those companies. So thanks for the questions, David.

Larry Keusch

analyst
#10

It's good to know that everybody's safe. Liam, I wanted to perhaps begin with — when you consider April, you gave us some detail on certain segments of the business. But what can you share regarding how April is shaping up? And more specifically, how are we viewing the different regions — the Americas, EMEA, and then Asia Pacific?

Liam Kelly

executive
#11

Larry, given that guidance has been withdrawn, I'm going to attempt to avoid talking about results within the quarter. What I will do is describe what took place when we went into the COVID-19 crisis. I'll describe what took place in EMEA and then what took place during March in the Americas. So — the COVID pandemic moved from Asia into EMEA first. As hospitals came to realize that far more patients were arriving with respiratory conditions, we received an enormous volume of orders for our respiratory products. And after that, as patients then moved through the hospital into the intensive care unit, we received more orders in our Anesthesia portfolio for airway management products, circuits, ET tubes, products of that kind. And then roughly a week or 10 days afterward, since these patients required vascular access, we observed a surge in our Vascular portfolio across EMEA. The Americas followed not long after that; and we witnessed nearly the identical pattern in which there was a rise in respiratory products, a rise in airway management products, and I would anticipate that a rise in vascular products comes next, based on that same pattern we observed in EMEA.

Larry Keusch

analyst
#12

All right. To wrap up that line of thinking, where would you say China stands at this point — is a recovery visible there? Then a separate question: I recall you mentioning that 60% of UroLift procedures happen outside the acute care setting. Do you see ways you could help shift more of that out of the hospital right now, so that maybe some of it could return more quickly if you're able to relocate it into a doctor's office or an ambulatory surgical setting?

Liam Kelly

executive
#13

Yes. I'll take the second part first. The thing that gives me encouragement is our knowledge that capacity exists in the ASC, especially in the office environment. We're also aware that this is a highly effective procedure with excellent outcomes, and we know it's a profitable procedure in both of those settings. With all of that established on a fact basis, from there it depends heavily on a practice-by-practice basis. When a urologist has an office setting and performs some work at a hospital, then naturally that physician has the flexibility to shift it to an ASC or an office environment. If that isn't the case, then — then relocation becomes less likely. But capacity does exist, Larry, and whenever capacity exists, we expect there to be flexibility to shift from the hospital to the ASC or the office. On the first part of your question about what we observed in China: what we observed during February and March was procedures starting to return, especially in March as they ramped up, and it depends greatly, I suppose, from city to city. In April, residents of Hubei were actually permitted to travel really across the entire country, as the lockdown ended in that part of the world; but what we observe in Shanghai specifically is that as we approached the end of March, we began to see procedures reaching some sense of normalcy toward the end of March, and we expect Beijing to follow suit extremely quickly. A lot of our business takes place down in the Eastern Seaboard, Larry, so we expect to return to some level of normalcy as we move through this quarter or quarter 2.

Richard Newitter

analyst
#14

Richard Newitter from SVB Leerink here. First off, Liam, regarding those long-range plan targets — the margin trajectory in particular — I realize you pulled 2020 guidance, but a lot of your spending is within your own control. And perhaps if you simply took your base case — you mentioned you were planning for multiple scenarios after COVID — but assuming that base case, do the long-range margin targets remain attainable, perhaps not 2021, but within, let's say, a 2-year window? Any color you can offer there?

Liam Kelly

executive
#15

Yes. Rich, I appreciate the question. Let me start off by saying, Rich, that we still believe our product portfolio can hit the 67%, 60%, 61% and 30% plus levels that we announced a few years back. That said, since we've just withdrawn our full year 2020 guidance owing to the uncertainty around COVID, it would be very hard for me to sit here at this moment and claim we can still get to those goals by 2021. We also need to see countries reopen. We certainly need the U.S. to reopen and procedures to come back. Once that happens, we'll have a clearer picture of the timeframe in which we can reach those goals. But sitting here today, I remain quite confident about hitting those longer-term goals. The sole uncertainty in my mind concerns the timing. And I'd like to observe the recovery before providing more detail on that.

Richard Newitter

analyst
#16

All right, that makes sense. Understood. Perhaps just one additional item. It's clear that acquisitions have occupied a key place in Teleflex's approach for quite a few years at this point. I'm simply wondering — you walked through where you stand on liquidity, but how did all of that business development work shift once COVID arrived?

Liam Kelly

executive
#17

Sure. Clearly, I continue to believe that putting our cash to work through M&A is still what we'd prefer to do, though even so, because there's so much uncertainty around how long the COVID-19 crisis could persist, it seems sensible to expect that deal activity will decelerate under these conditions. Rich, I believe you raised a crucial issue — our leverage ratio sits at roughly 2.6x as of now, which puts us in a fairly solid position. So in the near term, I'd expect us to be somewhat careful and conservative. That said, looking at the medium term, acquisitions will certainly keep playing a significant part in our evolution from a company growing at a medium rate with margin expansion into one growing at a high rate with margin expansion. And the new landscape means sellers are going to be evaluating prices that stood far higher just 2 months back. That could actually create a chance for a business such as Teleflex, given where our liquidity stands today. With COVID-19, we find ourselves in somewhat unfamiliar territory. Consequently, I want those who invest in us to feel at ease — we're going to stay every bit as disciplined as we've always been when determining which targets make sense, and doing a transaction worth a billion dollars doesn't strike me as appropriate given present conditions. So we'll remain careful, and we'll put the strength of our balance sheet first as this situation keeps changing.

Shagun Singh Chadha

analyst
#18

Liam, I'm simply wondering whether you believe we might witness a stretch of better-than-normal age growth during Q3, when doctors start clearing the backlog and patients book their procedures before autumn arrives — that being ahead of when flu season kicks off, or out of worry about a second wave hitting in the fall? Then I have one more question.

Liam Kelly

executive
#19

Well Shagun, the way I view things at this moment, and like I mentioned previously, is that we're seeing states starting to reopen. My sense is that a great deal will be learned over the coming month, and everything hinges on whether a COVID-19 spike shows up or those curves keep flattening; from my perspective, consumer confidence is the whole story. What I'm truly watching for is the moment folks head back to their dentist, and obviously dentistry isn't our line of work, but should people start doing that — and should I notice my own friends visiting the dentist, that would tell me we're extremely near to people returning to an office and an ASC for a UroLift procedure. And should that occur during the second quarter, and it appears it will kick off in the second quarter, I'll repeat my earlier point. There's room to perform those UroLift procedures, which happen to be the ones hit hardest when some of these procedures got postponed; therefore, my expectation is that during Q3 and Q4, many of those procedures would return. Not long ago I spoke with a urologist, and that person confirmed exactly what I figured he would — that not a single UroLift procedure has been canceled by him. He has merely pushed them to a later date; thus, in his practice those patients remain on the schedule right now to get that procedure.

Shagun Singh Chadha

analyst
#20

That's quite useful. Now, a question about MANTA. You kicked off a complete rollout on January 1. Could you share any insight into the level of uptake you witnessed up to the middle of March? Any details regarding procedure volumes? And what did sales look like during Q1?

Liam Kelly

executive
#21

Sure, of course. Those of you who follow our story are aware that we converted 4% of the market in the prior year. This year, our objective was to reach 8% conversion of the worldwide market. I can share that MANTA was doing extremely well before COVID hit. During January and February, we observed considerable expansion; if I isolated January and February, and took 2 months of the worldwide market, we essentially converted roughly 6% of the global market on a pro forma basis, based on — just under the revenue we brought in during January and February. When we reached the final 2 weeks of March, and I'll provide the identical figures I shared for UroLift, we observed a 35% drop across the last 2 weeks of March relative to the first 11 weeks, simply because procedures were being deferred, yet adoption has progressed very nicely. The price point matches precisely what we anticipated. And once more, when these procedures resume, we expect this product to resume as well; this is among the products we're deploying within certain digital tools, the telehealth tools I referenced during my prepared remarks, for training physicians, even when our salespeople are unable to enter the office; and finally, we have ready the 20-plus associate sales reps we intended to have supporting this product, and they are engaged and will be prepared as soon as procedures begin returning to the hospitals.

Anthony Petrone

analyst
#22

Anthony Petrone here, filling in for Raj. It's great to hear that all of you are in good health, and best of luck to everyone as we navigate the current cycle. I have a couple of questions about UroLift. Regarding the franchise's present margin profile, and taking into account that you have both UL2 and UL available, what is the current status of UroLift's margins? Also, perhaps you could provide an update on the OUS expansion plans. My understanding was that Japan was slated for at least a soft rollout in the first half. What effect does COVID have on the OUS expansion plans for UroLift? Then I have one follow-up question.

Liam Kelly

executive
#23

All right. The core margin profile for UroLift hasn't changed, Anthony. It remains in the mid-70s. Our objective continues to be rolling out UL2 to bring that into the high 70s. Because of COVID-19 and the fact that the FDA has been concentrated on handling COVID-19, there will be a minor delay to our 510(k) submission, so that will likely land in the June, July timeframe, and after that we'll face a 60-day, 90-day review prior to bringing the product to market. I mention that because it will affect the Japan rollout. We anticipate generating revenue in Japan early in 2021. We will probably now be generating revenue in Q1 or — or excuse me, from Q1 to Q2 — unlikely to move to Q3, though it could move to Q3. It truly hinges on the review time. But we will still be generating revenue in 2021. And I'd like to remind everyone that in our LRP, no revenue for Japan was contemplated; so we still envision that we will be generating revenue in Japan, most likely around the Q2-ish time frame, following the reimbursement approval.

Anthony Petrone

analyst
#24

Then, for a follow-up, beyond the coronavirus, when you run your own internal modeling, any perspective on the economy? You brought up that 25% are elective procedures, so the Teleflex portfolio looks fairly resilient in a recession. Still, any opinions on the economy, unemployment rates, how that factors in? And what's the internal thinking on that?

Liam Kelly

executive
#25

Right. So no sector can escape a recession's effects; however, I'm certain as all — every analyst knows, the area that is likely more protected is medical devices. People, regardless of whether the economy is growing, lagging, or in recession, people still become sick, and our products are needed. Part of the rationale for how we built our portfolio and truly concentrating 2/3 of it on nonemergent critical procedures is precisely that, to make sure those procedures could not be delayed. It's serving us well in the COVID-19 crisis we're facing at this moment, since such a small portion of our overall portfolio is affected by procedure postponement. That identical fact pattern would apply to Teleflex in a recession as well, where procedures would not be in a position to get delayed; and even then, our procedure that is probably the most elective, the UroLift, the health care economics on that are so strong that even in a recession, it is saving the health systems money as more patients opt for a UroLift procedure.

Matt Taylor

analyst
#26

So, I had a couple. The first thing — I appreciate that cadence you described regarding the ordering patterns for respiratory, airway management, and vascular access. I suppose I was curious whether you could tell from the trends — you mentioned 44% growth, I believe, in March. Based on what you've observed since, do you think a lot of that was stocking, or do you think it's actually being consumed given the large number of COVID patients in those centers?

Liam Kelly

executive
#27

That's a great question, Matt. What we observed at the end of the quarter — and as I mentioned in my prepared remarks, we brought a substantial backlog into the quarter. So our typical backlog of orders, in these product categories and for our entire business, would be roughly 1 day of sales. When we entered April, that was more than — it was nearly 3 times the usual backlog we tend to carry. We ramped up production of these respiratory products, some by 200%, to try to address the pandemic. These products will be used by the hospitals treating COVID patients. Every patient placed on a ventilator is going to need a filter — a bacterial filter. It safeguards the patients and those around them, but it also safeguards the ventilator so that cross infections don't occur. Every patient will also have a HEPA filter, which is a heat moisture exchange filter, to perform the function of the nose. We believe these products are being consumed. Without a doubt, I think after the pandemic, hospitals and distributors will actually keep more inventory of these products. I think people — as I also said in my prepared remarks — is it a V-recovery? Is it U-recovery? Or is it a W? So you drop down to bigger stockpiles, and we're talking with government agencies right now because we're ready to keep manufacturing these products, but we want to know what government agencies intend to do regarding their stockpile actions for key respiratory, Anesthesia, and Vascular products.

Matt Taylor

analyst
#28

All right, that's clear. And you gave us quite a few helpful aggregate figures on UroLift. I actually have one additional question on that topic. You referenced speaking with certain customers who had not called off procedures. I'm curious whether you happen to know, in general terms, if you could describe for us the typical lead time on scheduling those procedures. And then, when it comes to bringing patients back into the funnel, does a significant amount of testing or evaluation need to occur? Or does it happen fairly fast and simply?

Liam Kelly

executive
#29

Let me take the second part first. If BPH is what you're dealing with, Matt, this isn't a condition that improves on its own. So typically a urologist relies on IPSS scores, and obtaining a patient's IPSS scores is an extremely straightforward method — roughly 5 minutes — and in many cases the patient can complete it online on the urologist's behalf. So nothing extensive in the way of testing is required to get that patient repositioned. From our digital media and regional DTC campaigns, we've learned that for a high rate of acceptance for the procedure, a patient has to be scheduled within about 4 weeks. That's what the DTC tells us. And my sense is it's roughly that 4-ish weeks, Matt. And like I mentioned, there's capacity, especially in the office and the ASC, to get these patients scheduled and bring in newer patients. Naturally, offices are going to need to put certain procedures in place regarding social distancing and face masks, however they deem appropriate, to get things up and running. But I believe it should be — from my own perspective, at least — that since urology practices now know which states are opening, we're once again using some of our digital tools to train urologists, revisiting some of that training, to ensure they're ready and prepared to re-engage with their patients. And as I noted in my prepared remarks, our DTC campaigns are also set to reengage with those men to increase their awareness of BPH.

Drew Stafford

analyst
#30

Drew here, filling in for Matt. I'd like to dig a bit deeper into MANTA. So I suppose, with conditions starting to ease somewhat over the coming 2 months on the hospital side, I'm curious whether you've formed any view about the way they'll rank certain items above others. And more precisely, I'm asking, going past what you've already covered, whether there's any danger that instruction on new offerings like MANTA might get delayed in the meantime while hospitals catch up on backlogs and give priority to OR time?

Liam Kelly

executive
#31

Sure, Drew, I appreciate the question. I'll give you a little more context about how the North American market looked from a revenue standpoint in the first two months of our full launch — before that we'd been running a limited launch. As customers moved into Q1, existing customers accounted for 80% of revenue. So utilization is really the whole game here. By now those customers have been trained, and they're already operational. TAVR procedures drove a big majority — in the high 80s — of our revenue. That's why we think TAVR procedures ought to recover fairly early in the cycle, and that ought to work in our favor. Drew, I mentioned this during my prepared comments too — within the Interventional Access business unit, we're leveraging digital resources to educate our customers about MANTA. Beyond that, we've posted a number of instructional videos so those customers can access them. Additionally, when hospitals permit sales representatives to return, they're granting access for essential training sessions tied to new products. Our company has also secured protective clothing supplies for the sales team, which enables them to go back into hospital environments.

Drew Stafford

analyst
#32

All right, that's encouraging to hear. Then, for my quick second question, over these past 2 weeks there's been a lot of talk about delays in clinical trials throughout Medtech. Clearly, a substantial portion of your growth has come from new products. From what you're saying, it sounds like all of your R&D work on those will keep going. But is there anything significant on the clinical trial side that might be paused for a while?

Liam Kelly

executive
#33

Yes. Thanks; there was a single MANTA trial we were sponsoring, though it was extremely close to finishing. So my sense is the effect won't be large. As we emerge on the other side of COVID, we'll evaluate new products. Drew, I believe it's a bit too soon to say anything about where things stand with new products; however, we didn't have — we did have certain clinical trials underway in the Interventional Urology business unit, in MANTA, and in the Interventional Access business unit. And clearly, new products are always in development and in the mix. Oddly enough, one product that actually benefited from COVID-19 was our ISO-Gard Mask, a product we had originally created to prevent clinicians from re-breathing gases from a patient. And we — that product is now — we're preparing to file it for an emergency authorization to fight COVID. The sole other product I can think of that might be affected would be EZPlas, for which we did send the data to the FDA, and we had expected to meet with the FDA in — we were meant to submit in March and meet them in April. In fact, we sent our data at the end of February; however, the meeting with them has been delayed. So we're now attempting to reschedule it for May or June.

Brian Weinstein

analyst
#34

You have discussed the elective procedure side quite a bit, yet clearly we have all been picking up plenty regarding nondeferrable procedures — even things such as appendicitis cases; MI patients have declined; cancer diagnostics are — we're being told by companies that new patients clearly are getting hit there too, with fewer cancer diagnoses; so trauma could be reduced with fewer individuals moving around. I realize you'd rather not say much about April at this point, but are you currently observing any effect on the remaining 2/3 of the business that would roughly match what all of us are hearing broadly regarding these nondeferrable type cases?

Liam Kelly

executive
#35

From where we sit, aside from the COVID impact, we haven't observed any effect from the things you just described. And at this moment, since the situation remains fairly fluid, Brian, it would be hard to separate what belongs to this impact versus that impact. Still, based on what our frontline folks who deal with customers are telling us, it comes down to either COVID or non-COVID, and whatever procedures get delayed are more than made up for in that scenario. Whatever procedures get delayed are being more than compensated for by patients arriving as a result of COVID's effects. And the portions of our business affected, clearly, by procedures are extremely small. Yet a person will still suffer a heart attack. The EZ-IO will still be required. If you're being taken in — after that heart attack, into the emergency room, a laryngeal mask will still be needed. You're still going to wind up in the intensive care unit. A PICC or a CVC will still have to be placed in you, you're still going to need to be placed on a ventilator, and one of our ventilation circuits plus our humidification system will still have to be used. So that represents our normal patient flow. Therefore, if someone suffers a heart attack, I believe it remains quite improbable that they will — that they won't head to the hospital or summon the ambulance, even under these circumstances.

Brian Weinstein

analyst
#36

All right, and as a follow-up to something asked earlier about inventory levels and so forth — I'm wondering in particular whether ordering behavior from distributors has shifted significantly at this stage, excluding COVID-19 items. Are they reducing stock, building it up? Will we be sitting on this call a quarter from now, or two quarters out, learning about adjustments related to how your distribution partners handle your products?

Liam Kelly

executive
#37

Yes, thank you. In January and February, what we observed was distributors — Owens & Minor, Cardinal, that kind of distributor — drawing down inventory. And across the entire quarter, there was destocking. Distributors didn't respond to the COVID crisis as agilely as might have been expected. So for our businesses, we did experience cumulative destocking during the quarter. Our Vascular business and our Anesthesia business took the biggest hit.

Dave Turkaly

analyst
#38

Liam, clearly, you're in a position where you have many discussions that might help plenty of us if we were able to have some comparable conversations. You provided plenty of detail, so thank you for that, regarding the back half of March. My assumption is that April looked much the same. And once more, it's good to hear that you lean more toward the critical care, nonelective side; though this isn't guidance, just opinion. I'd simply like to ask you, from where you sit today, as you look ahead, do you believe the worst is behind us when it comes to elective procedures, or do you believe we aren't yet in the clear and this will keep going?

Liam Kelly

executive
#39

So as I examine the data on COVID-19's occurrence, worldwide, we've — and the flattening of the curves gives me encouragement. And that data, clearly, all of us are able to see. To me, everything comes down to consumer confidence. Everything comes down to consumer confidence. When will folks feel confident enough to return to an ASC, to return to an office and to return to a hospital. And from my chair, and thank you for all those kind remarks about me. But unlike anyone else, I don't possess a crystal ball. And I believe everything comes down to consumer confidence; now I realize that people are and I realize clinicians are keen to get back to work since they believe a great deal of harm is being done to individuals who are suffering mild strokes and not going to the emergency room, and the fact that states are reopening gives me encouragement. As I mentioned, when I was discussing UroLift, over the coming weeks, states accounting for 60% of our UroLift revenue will be reopening. Now the following piece of that is consumer confidence. And for me, that is essential, is the consumer feeling confident enough to come back in and get procedures done.

Dave Turkaly

analyst
#40

Understood. You brought up 2 sites you operate, and from what you're saying, the effect there seems fairly small. Could you give us a quick reminder — I realize you have a huge number, but roughly how many do you run, I'd guess, and they're viewed as essential, yet even within the Americas, are most of your remaining plants running at full capacity? And did COVID cause any disruption at any of those other sites? Our 3 strategic locations, described by geography, are Mexico, the Czech Republic and Malaysia. Regarding Malaysia, only a few days ago we received notice that we may increase output to 100% capacity; previously we stood at 50%; we held sufficient inventory in the channel, which let us direct that 50% capacity toward COVID-related products. As we now scale up to 100%, we'll be in a position to rebuild the stocks we had drawn down. Clearly, we produce at a number of plants across the United States. The Twin Cities is a region where we concentrate within each of those facilities. Every site we operate in the Americas is functioning. The 2 — Malaysia sat at half capacity while our Indian plant was shut, and we expect it to reopen before long. Still, we hold adequate inventory to supply carriers for that Indian site too, just so that's clear.

Matthew Mishan

analyst
#41

Liam, I'd like to grasp the OEM picture better, and apologies if this was covered, but what portion of that gain stemmed from the HPC acquisition? And were customers merely building inventory because of supply chain worries?

Liam Kelly

executive
#42

As I mentioned, it rose 17.5%; roughly half and half. One half of it originates from HPC, with the other half originating from our core business. Our OEM business serves other companies. Typically, then, you won't see the stocking up effect in an OEM business; things proceeded normally; the single effect visible in that growth rate stems from the sterilization. As you may remember, OEM took a hit because of delivering particular products to that Atlanta sterilizer. So some of that product did flow through during this quarter, quarter 1. That, I believe, is the sole effect I flagged for OEM.

Matthew Mishan

analyst
#43

All right. Then, Tom, regarding cash flow — obviously, the ongoing consideration tied to pension payments during the quarter is visible — are those the main nonrecurring items for 2020? Also, what's your view on the inventory buildup you've had going on that's been leveling out over the course of the year?

Tom Powell

executive
#44

Yes, those represent the main nonrecurring items. In terms of inventory, I'd say we increased it somewhat during the first quarter — a few last-time purchases plus stockpiling so we'd have enough on hand to navigate the COVID situation. So looking ahead to the remainder of the year, we don't expect any widespread ongoing buildup, with a single exception. We'll keep building UroLift. Our days of inventory on hand stood at roughly 15 days, and we aim to raise that figure so we have plenty of that product on hand, in case there's a fairly substantial ramp once we move beyond the elimination of elective surgeries, so to speak. So aside from that, I'd say we don't expect to keep growing inventories. That said, we've reached a point of improved visibility into where demand stands and need to ensure we're keeping pace with it — until we have that precise visibility, we might see some nonrecurring items in either direction.

Kristen Stewart

analyst
#45

I hope everyone is doing well and staying safe, wherever you might be. I'd like to return to UroLift — sorry to keep bringing it up — but I want to better grasp how the split breaks down. You've mentioned that most procedures take place in an office or ASC setting. Could you help us understand the office portion of that split? My impression was that ASCs handle the bulk of cases. Also, I believe you told David that the typical patient age is roughly 60. Would it be reasonable, then, to conclude that from a payer standpoint, managed care covers the larger share? What's your estimate for the typical co-pay amount? And economically speaking, would there be any worries if a recession-like scenario, such as this COVID period, were to occur?

Liam Kelly

executive
#46

Alright. So of that 60%, it's approximately an even division — roughly half ASC, half office. We don't really see it tilted toward either one. And frankly, many of the ASCs resemble an office setting in most respects. As for your average age question: private insurer payment accounts for about 30-ish percent of the total, if my memory serves. Pinpointing procedure requirements sooner is something we've been exploring through certain clinical trials. On whether a recession would bring a co-pay into play: yes, a co-pay definitely exists; however, as everyone knows, that's the norm across every payment method these days. It's simply, I believe, a reality that health care spending rises after we pass age 55, and that shouldn't — well, between ages 50 and 65, roughly 10% of your lifetime health care expenditure occurs. From 65 to 85, you'll actually spend around 60% of your health care. That pattern has persisted across numerous recessions without producing a major effect. You also have to weigh the co-pay against the discomfort a patient experiences because of BPH. If urinary retention is involved, that means catheterizing yourself 10 times daily. Then there's the broader health care economics for the system: performing a BPH procedure lowers the total cost of treating that patient by getting them off-farm or avoiding acute procedures. So the health care economics case for UroLift is likely among the strongest, which explains why the product has succeeded so well.

Kristen Stewart

analyst
#47

All right, and I just want to make sure I have this right — you mentioned that during the final 2 weeks of March, UroLift sales were running down 64%, and is that measured against the same period a year earlier?

Liam Kelly

executive
#48

No, no. What it is — if you look at the first 11 weeks, and then set the last 2 weeks against those first 11, the decline comes to 64% for those last 2 weeks versus the first 11, Kristen.

Kristen Stewart

analyst
#49

Okay. So that's not year-over-year? Got you.

Liam Kelly

executive
#50

No.

Kristen Stewart

analyst
#51

All right, that's useful. Could you tell us what that figure looks like compared with the same period a year earlier, perhaps? Or simply put it in context for us?

Liam Kelly

executive
#52

Honestly, I don't have that number — I'm not sure what it was. I felt a different measure worked better. And the reason I preferred another measure is so that those of us in the investment community could grasp what we were accomplishing before COVID made its impact felt. So during the initial 2 months of that quarter, the business was expanding by more than 38%. After that, I believed the greatest value for the investment community would come from knowing what took place during the final 2 weeks versus the first 11. That's the reason I considered it suitable to provide that measure to the investment community, giving them a sense of what we observed on the ground with the UroLift procedure.

Kristen Stewart

analyst
#53

All right, so compared with that figure, the shift from there afterward fell 64%.

Liam Kelly

executive
#54

Correct; and I'll provide the monthly growth rate, Kristen, in case that's useful; these are year-over-year numbers. So Iub, UroLift increased by more than 38%, as I mentioned, during January and February, and after that it dropped 3.3% in March.

Jake Elguicze

executive
#55

Appreciate it, operator, and I want to thank all of you for being on the call today; that wraps up the Teleflex Inc. First Quarter 2020 Earnings Conference Call. Enjoy the rest of your day.

Operator

operator
#56

Everyone, that brings us to the end of today's call. We appreciate your participation. You're free to hang up at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.